Merck Januvia Is First DPP-4 Inhibitor To Reach FDA
This article was originally published in The Pink Sheet Daily
Firm says the oral DPP-4 inhibitor has a mid-October user fee date for a type 2 diabetes indication.
You may also be interested in...
The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.